A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combination of Cemiplimab and Chemotherapy in Adult Patients With Non-Small Cell Lung Cancer That Can be Treated With Surgery
Running, not enrolling · Phase 2 · Has a placebo group
Conditions studied: Resectable Non-small Cell Lung Cancer
In brief
This study is researching an experimental drug called fianlimab (also called REGN3767) with two other medications called cemiplimab and platinum-doublet chemotherapy, individually called a "study drug" or collectively called "study drugs", when combined in this study. The study is being conducted in patients who have resectable stage II to IIIB (N2) non-small cell lung cancer (NSCLC) that can be treated with surgery. The aim of the study is to see how effective the combination of fianlimab, cemiplimab, and chemotherapy is in comparison with cemiplimab and chemotherapy as peri-operative therapy in participants with NSCLC. The study is looking at several other research questions, including: * What side effects may happen from taking the study drugs * How much of each study drug is in the blood at different times * Whether the body makes antibodies against the study drugs (which could make the drugs less effective or could lead to side effects) * How administering the study drugs might affect quality of life
Key facts
- Study ID
- NCT06161441
- Run by
- Regeneron Pharmaceuticals
- People needed
- 195
- Starts
- 2024-07-16
- Expected to finish
- 2029-11-04
- Last updated by the study team
- 2026-05-28
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- University of Illinois — Chicago, Illinois, United States
- University of Kansas Cancer Center-Westwood — Westwood, Kansas, United States
- Henry Ford Health System — Detroit, Michigan, United States
- Mercy South — St Louis, Missouri, United States
- University of Rochester — Rochester, New York, United States
- Kaiser Permanente Northwest — Portland, Oregon, United States
- Virginia Cancer Care Specialist, PC — Fairfax, Virginia, United States
- Eastern Health — Box Hill, Victoria, Australia
- St Vincent's Hospital — Fitzroy, Victoria, Australia
- St John of God Murdoch Hospital — Murdoch, Western Australia, Australia
- Orlandi Oncologia — Providencia, Metropolitan Region, Chile
- Clinica Santa Maria — Santiago, Providencia, Chile
- Centro de Oncologia de Precision — Las Condes, Region Metropolitana, Santiago, Chile
- Oncocentro APYS — Viña del Mar, Valparaiso, Chile
- Centre de Oncologie de Gentilly — Nancy, Grand Est, France
- Institut de Cancerologie de l'Ouest — Saint-Herblain, Nantes, France
- Centre Hospitalier Universitaire (CHU) Bordeaux — Bordeaux, New Aquitaine, France
- CHU Limoges — Limoges, New Aquitaine, France
- APHP - Hopital Ambroise Pare — Boulogne-Billancourt, France
- CHU Dijon — Dijon, France
- Centre Hospitalier Universitaire de Nantes Hopital Guillaume et Rene Laennec — Nantes, France
- Uneos - Hopital R Schuman — Vantoux, France
- Chi Creteil — Créteil, Île-de-France Region, France
- Hopital Cochin — Paris, Île-de-France Region, France
- Clermont Oncology Center — Clermont, Florida, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.